NephroCheck® Test System
Novel Biomarker Identification. Rapid Risk Assessment. The innovative end result of Astute Medical's novel biomarker identification, the NephroCheck® Test provides risk assessment of critically ill patients who may develop acute kidney injury. A single-use cartridge designed to detect biomarkers of acute kidney injury (AKI), the NephroCheck® Test is available for use with the Astute140® Meter. By producing results in approxim…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Novel Biomarker Identification. Rapid Risk Assessment.
The innovative end result of Astute Medical's novel biomarker identification, the NephroCheck® Test provides risk assessment of critically ill patients who may develop acute kidney injury. A single-use cartridge designed to detect biomarkers of acute kidney injury (AKI), the NephroCheck® Test is available for use with the Astute140® Meter. By producing results in approximately 20 minutes, the test aids clinicians in making more rapid responses for critically ill patients.
The diagnosis of AKI is still made on the basis of a change in serum creatinine or urine output, both of which are derived from an altered glomerular filtration which identifies dysfunction not damage. Dysfunction only becomes evident when more than 50% of the renal mass is compromised and implies that it may be a later phenomenon in the time course of an AKI. Unlike these surrogates, the NephroCheck® Test identifies actual renal stress, before damage or dysfunction has occurred.
The test consists of two novel biomarkers, TIMP-2 and IGFBP-7, which alert the clinician of ongoing kidney cellular stress before kidney dysfunction becomes apparent. TIMP-2 and IGFBP-7 both are involved in G1 cell cycle arrest during the very early phases of cellular stress and are robust measures of risk for AKI manifesting within the next 12-24 hours.
